Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
October 06, 2014 01:15 ET
|
NOVARTIS FINANCE S.A.
Phase I/II studies will evaluate Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational immunotherapy Opdivo® Combination studies will evaluate compounds that...
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
August 31, 2014 16:00 ET
|
NOVARTIS FINANCE S.A.
Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen[1] On all-cause mortality, LCZ696 doubled the effect...
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
August 11, 2014 01:15 ET
|
NOVARTIS FINANCE S.A.
LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF PARADIGM-HF is the largest heart failure...
Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook
July 17, 2014 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales grew 2%[1] in Q2, with core operating leverage across Q2 and H1 Net sales of USD 14.6 billion grew 2% (+2% cc[2]) in Q2; USD 28.7 billion (+2%, +2% cc) in H1 Strong operating income...
Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day
June 18, 2014 01:00 ET
|
NOVARTIS FINANCE S.A.
New Novartis focused on three leading businesses with innovation power and global scale Pharmaceuticals building business depth in Dermatology, Heart Failure, Respiratory and Cell Therapy,...
Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary
May 14, 2014 23:00 ET
|
NOVARTIS FINANCE S.A.
Litigation settlement upholds validity of US patents covering polymorphic forms of Gleevec and permits Sun Pharma subsidiary to launch a generic version on February 1, 2016 Patents are vital to...
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
April 29, 2014 15:30 ET
|
NOVARTIS FINANCE S.A.
Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option[1] Median duration of response to Zykadia was 7.4...
Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio
April 24, 2014 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales of USD 14.0 billion up 1%[1] (+3% cc[2]) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating...
Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics
April 22, 2014 01:00 ET
|
NOVARTIS FINANCE S.A.
Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines...
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
April 09, 2014 01:00 ET
|
NOVARTIS FINANCE S.A.
New leaders to continue to build global scale and innovation power in two of the leading Novartis businesses Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as...